Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Greta, Hultqvist"'
Autor:
María Pagnon de la Vega, Stina Syvänen, Vilmantas Giedraitis, Monique Hooley, Evangelos Konstantinidis, Silvio R. Meier, Johanna Rokka, Jonas Eriksson, Ximena Aguilar, Tara L. Spires-Jones, Lars Lannfelt, Lars N. G. Nilsson, Anna Erlandsson, Greta Hultqvist, Martin Ingelsson, Dag Sehlin
Publikováno v:
Acta Neuropathologica Communications, Vol 12, Iss 1, Pp 1-16 (2024)
Abstract Deposition of amyloid beta (Aβ) into plaques is a major hallmark of Alzheimer’s disease (AD). Different amyloid precursor protein (APP) mutations cause early-onset AD by altering the production or aggregation properties of Aβ. We recentl
Externí odkaz:
https://doaj.org/article/e1e6c9096c0f4e3e9f714a2564198215
Autor:
Inga Petersen, Ana Godec, Farahnaz Ranjbarian, Anders Hofer, Claudio Mirabello, Greta Hultqvist
Publikováno v:
PLoS ONE, Vol 19, Iss 8, p e0308521 (2024)
The aggregation of α-Synuclein (αSyn) is strongly linked to neuronal death in Parkinson's disease and other synucleinopathies. The spreading of aggregated αSyn between neurons is at least partly dependent on electrostatic interactions between posi
Externí odkaz:
https://doaj.org/article/f0e47206191945239ecfe2546464572c
Autor:
Inga Petersen, Muhammad Ilyas Ali, Alex Petrovic, Anders Jimmy Ytterberg, Karin Staxäng, Monika Hodik, Fadi Rofo, Sina Bondza, Greta Hultqvist
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTSoluble aggregates are reported to be the most neurotoxic species of α-Synuclein (αSyn) in Parkinson’s disease (PD) and hence are a promising target for diagnosis and treatment of PD. However, the predominantly intracellular location of
Externí odkaz:
https://doaj.org/article/fce9db4fa4384fd3ad0fdb528d47e125
Autor:
Tobias Gustavsson, Nicole G. Metzendorf, Elin Wik, Sahar Roshanbin, Ulrika Julku, Aikaterini Chourlia, Per Nilsson, Ken G. Andersson, Hanna Laudon, Greta Hultqvist, Stina Syvänen, Dag Sehlin
Publikováno v:
Alzheimer’s Research & Therapy, Vol 15, Iss 1, Pp 1-16 (2023)
Abstract Background Brain-directed immunotherapy is a promising strategy to target amyloid-β (Aβ) deposits in Alzheimer’s disease (AD). In the present study, we compared the therapeutic efficacy of the Aβ protofibril targeting antibody RmAb158 w
Externí odkaz:
https://doaj.org/article/e33e7887ceef437fa638b612c0f45d72
Autor:
Andrés de la Rosa, Nicole G. Metzendorf, Jamie I. Morrison, Rebecca Faresjö, Fadi Rofo, Alex Petrovic, Paul O’Callaghan, Stina Syvänen, Greta Hultqvist
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-17 (2022)
Abstract The blood–brain barrier (BBB) greatly limits the delivery of protein-based drugs into the brain and is a major obstacle for the treatment of brain disorders. Targeting the transferrin receptor (TfR) is a strategy for transporting protein-b
Externí odkaz:
https://doaj.org/article/aa4b075b0c2048ffaa30444b0494af4a
Autor:
Fadi Rofo, Nicole G. Metzendorf, Cristina Saubi, Laura Suominen, Ana Godec, Dag Sehlin, Stina Syvänen, Greta Hultqvist
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-19 (2022)
Abstract Background Aggregation of the amyloid-β (Aβ) peptide in the brain is one of the key pathological events in Alzheimer’s disease (AD). Reducing Aβ levels in the brain by enhancing its degradation is one possible strategy to develop new th
Externí odkaz:
https://doaj.org/article/a3ccdd56160f4deebd423b5623878295
Autor:
Vinay Banka, Andrew Kelleher, Dag Sehlin, Greta Hultqvist, Einar M. Sigurdsson, Stina Syvänen, Yu-Shin Ding
Publikováno v:
Frontiers in Nuclear Medicine, Vol 3 (2023)
IntroductionAlzheimer's disease (AD) is characterized by the misfolding and aggregation of two major proteins: amyloid-beta (Aβ) and tau. Antibody-based PET radioligands are desirable due to their high specificity and affinity; however, antibody upt
Externí odkaz:
https://doaj.org/article/6801742a36c6424bbe26ac6aa36e9a16
Autor:
Fadi Rofo, Jos Buijs, Ronny Falk, Ken Honek, Lars Lannfelt, Anna M. Lilja, Nicole G. Metzendorf, Tobias Gustavsson, Dag Sehlin, Linda Söderberg, Greta Hultqvist
Publikováno v:
Translational Neurodegeneration, Vol 10, Iss 1, Pp 1-16 (2021)
Abstract Background Amyloid-β (Aβ) immunotherapy is a promising therapeutic strategy in the fight against Alzheimer’s disease (AD). A number of monoclonal antibodies have entered clinical trials for AD. Some of them have failed due to the lack of
Externí odkaz:
https://doaj.org/article/e3112d378ac74be8899dc991771ba21a
Autor:
Sahar Roshanbin, Ulrika Julku, Mengfei Xiong, Jonas Eriksson, Eliezer Masliah, Greta Hultqvist, Joakim Bergström, Martin Ingelsson, Stina Syvänen, Dag Sehlin
Publikováno v:
Pharmaceutics, Vol 14, Iss 7, p 1412 (2022)
Immunotherapy targeting aggregated alpha-synuclein (αSYN) is a promising approach for the treatment of Parkinson’s disease. However, brain penetration of antibodies is hampered by their large size. Here, RmAbSynO2-scFv8D3, a modified bispecific an
Externí odkaz:
https://doaj.org/article/88c4bd6ad03d434faef530bad90408ad
Autor:
Jamie I. Morrison, Alex Petrovic, Nicole G. Metzendorf, Fadi Rofo, Canan U. Yilmaz, Sofia Stenler, Hanna Laudon, Greta Hultqvist
Publikováno v:
Molecular Pharmaceutics. 20:1564-1576
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1f20efee36c8227df1195ba86d3c86f
https://doi.org/10.1021/acs.molpharmaceut.2c00768
https://doi.org/10.1021/acs.molpharmaceut.2c00768